EGLT Egalet Corporation

5.90
+0  (0%)
Previous Close 5.90
Open 6.00
Price To book 5.68
Market Cap 145.22M
Shares 24,614,000
Volume 657,500
Short Ratio 14.16
Av. Daily Volume 660,733

SEC filingsSee all SEC filings

  1. 8-K - Current report 17518390
  2. 8-K - Current report 17515958
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 162046307
  4. 8-K - Current report 162041547
  5. 8-K - Current report 161996402

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA filed December 1, 2016.
OXAYDO
Acute and chronic moderate to severe pain
Phase 3 to be completed 4Q 2017. NDA planned for 2018.
Egalet-002
Moderate to severe chronic pain
Approved January 9, 2017.
Egalet-001 (ARYMO ER)
Abuse-Deterrent Morphine

Latest News

  1. SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Egalet Corporation and Encourages Investors with Losses to Contact the Firm
  2. EGALET NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Egalet Corporation to Contact the Firm
  3. SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Egalet Corporation and Advises Investors with Losses to Contact the Firm
  4. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Egalet Corporation
  5. EGALET NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Egalet Corporation To Contact The Firm
  6. Latest Reports on Egalet and Illumina as the NASDAQ Continues to Hit Record Highs
  7. Here's Why Egalet Corp. Stock Fell 20% Today
  8. FDA Clears Egalet's Long-Acting Opioid Painkiller
  9. Egalet Corp (EGLT) Gets Approval But Fails On Labelling, Here’s What’s Next
  10. Egalet painkiller wins FDA approval but label disappoints
  11. EGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  12. FDA approves Wayne firm's tamper-resistant opioid medicine
  13. Egalet Receives FDA Approval for ARYMO™ ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain
  14. Egalet's long-acting opioid painkiller Arymo wins FDA approval
  15. Three Companies Set To Benefit From The 21st Century Cures Act: Who And Why
  16. Egalet's Best-In-Class Opioid Abuse Deterrent Continues To Impress
  17. Company News for December 19, 2016
  18. Analyst Sees Nearly 100% Upside In Egalet Following Latest Clinical Data
  19. Blog Coverage Egalet Announced Positive Results from Human Abuse Potential Study of Egalet-002
  20. Egalet Announces Positive Top-Line Results from an Intranasal Human Abuse Potential Study of Egalet-002

SEC Filings

  1. 8-K - Current report 17518390
  2. 8-K - Current report 17515958
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 162046307
  4. 8-K - Current report 162041547
  5. 8-K - Current report 161996402
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161982013
  7. 8-K - Current report 161973617
  8. 8-K - Current report 161936055
  9. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 161907559
  10. 8-K - Current report 161864885